Products Tulisokibart + Placebo
Tulisokibart + Placebo Phase 2 Active ⚡ Active Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Mar 29, 2022 → Jul 31, 2029
About Tulisokibart + Placebo Tulisokibart + Placebo is a phase 2 stage product being developed by Merck for Diffuse Cutaneous Systemic Sclerosis. The current trial status is active. This product is registered under clinical trial identifier NCT05270668. Target conditions include Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease.
Clinical Trials (5) NCT ID Phase Status Start Completion Indication NCT07486960 Phase 2 Recruiting Apr 22, 2026 Jan 11, 2030 Psoriatic Arthritis NCT07133633 Phase 2 Recruiting Sep 26, 2025 Feb 5, 2030 Radiographic Axial Spondyloarthritis NCT06956235 Phase 2 Active Jun 9, 2025 Jan 22, 2029 Hidradenitis Suppurativa NCT06829225 Phase 1 Completed Jun 13, 2024 Nov 11, 2024 Colitis, Ulcerative NCT05270668 Phase 2 Active Mar 29, 2022 Jul 31, 2029 Diffuse Cutaneous Systemic Sclerosis
Competing Products 20 competing products in Diffuse Cutaneous Systemic Sclerosis
See all competitors Product Company Stage Hype Score IVA337 + Placebo Inventiva Phase 2 Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) Eli Lilly Phase 2 rituximab Celltrion Phase 1 YM155 Astellas Pharma Phase 2 enzastaurin + gemcitabine + rituximab + oxaliplatin Eli Lilly Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Johnson & Johnson Phase 2 VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Johnson & Johnson Phase 2 Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + Gemcitabine AbbVie Phase 3 ABBV-525 AbbVie Phase 1 rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + Epcoritamab AbbVie Phase 1/2 Copanlisib + Venetoclax AbbVie Phase 1/2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 Epcoritamab + Lenalidomide AbbVie Phase 2 Venetoclax + Selinexor AbbVie Phase 1 Epcoritamab AbbVie Phase 1 Loncastuximab Tesirine and Epcoritamab AbbVie Phase 2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 bendamustine + navitoclax + rituximab AbbVie Phase 2 Epcoritamab AbbVie Phase 2 Epcoritamab (monotherapy) + Epcoritamab + Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + Gemcitabine and oxaliplatin + Epcoritamab (maintenance) + Rituximab and lenalidomide AbbVie Phase 1/2
Other Products from Merck